New Jersey S 919: Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

Status: Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee (as of 2020-01-27)

State: New Jersey · Session: 219 · Bill: S 919

Subjects: PHARMACEUTIC

Sponsors: Singleton, Troy

View New Jersey S 919 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.